Products & Pipeline

Utilizing the advantages of the proprietary Themaxyn® platform, Themis currently focuses its vaccine development on two attractive markets with high potential for returns: Emerging diseases and Infants & Adults.

Emerging diseases pose a rapidly increasing threat to developing and developed countries alike. Climate change and mass tourism are fueling this raise in outbreaks worldwide and for many diseases there are yet no efficient treatments or vaccinations available.

Vaccines are one of the most important, safe and efficient interventions to protect people from illness, disability and death. Themis is working on the improvement of currently licensed vaccines, but also on new vaccines to protect children and adults.

Pipeline Plan 2016

* Dengue GHIT grant funded until P1 completion
** under collaboration with Institut Pasteur